Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 12q14 Microdeletion Syndrome C4305140
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 12q14 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
12q14 Microdeletion Syndrome C4305140
A rare genetic deletion involving a segment of chromosome 12. It may lead to developmental delays, learning difficulties, and other health issues. Management is individualized and focuses on supportive therapies.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
12q14 Microdeletion Syndrome C4305140
0-2
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
12q14 Microdeletion Syndrome C4305140
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
12q14 Microdeletion Syndrome C4305140
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
12q14 Microdeletion Syndrome C4305140
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
12q14 Microdeletion Syndrome C4305140
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
12q14 Microdeletion Syndrome C4305140
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 12q14-microdeletion-syndrome-C4305140 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 12q14 Microdeletion Syndrome C4305140 | Discriminating power |
|---|---|---|---|
| Sexual development | May include ambiguous genitalia or absent puberty from impaired sex-steroid production. | Sexual development is not a defining feature in the supplied description. | High |
| Blood pressure | Hypertension is a recognized possible feature. | Hypertension is not established by the supplied description. | Moderate |
| Development and learning | Developmental delay is not a core described feature. | May involve developmental delay and learning difficulty. | High |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Disordered puberty or ambiguous genitalia with hypertension
This pattern fits an endocrine steroid-synthesis disorder better than a nonspecific microdeletion.
Moderate
Abnormal steroid-pathway evaluation
A clinician-confirmed pattern of impaired cortisol and sex-steroid production supports this diagnosis.
High
Need for lifelong endocrine replacement
The supplied description specifically indicates lifelong hormone replacement.
High
Choose 12q14 Microdeletion Syndrome C4305140 when
Early developmental delay with learning difficulty
These are the principal features described for the microdeletion.
Moderate
Chromosomal microarray shows a 12q14 deletion
A confirmed deletion is the defining laboratory finding.
High
Supportive developmental care is the main need
Management is described as individualized and supportive rather than hormone replacement.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 12q14 Microdeletion Syndrome C4305140 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal pattern may support impaired steroid synthesis; exact cutoffs are not supplied. | No characteristic steroid abnormality is established. | Interpret only with specialist endocrine review. |
| Chromosomal microarray | Not the defining test for this enzyme disorder. | May identify a deletion involving 12q14. | A reported deletion requires genetics confirmation and clinical correlation. |
| Blood pressure measurement | Hypertension may be present. | No specific blood-pressure pattern is established. | An abnormal reading is not itself a diagnosis. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine condition; exact survival and complication rates are not established here.
- Factors
- Hormone management, blood-pressure control, and puberty-related care may influence outcomes.
12q14 Microdeletion Syndrome C4305140
- Outcome
- Chronic congenital condition with variable developmental and learning impact.
- Factors
- Deletion extent, associated health issues, and access to supportive therapies may matter.
Time frame: Childhood onset with potentially lifelong effects; precise timelines are not established.
Diagnosis confirmation, individualized care, and associated findings should guide prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Pubertal impairment | Lack of puberty may occur and needs endocrine care. Not established from the supplied data. Do not infer fertility or treatment outcomes. |
| Hypertension-related risk | High blood pressure may require monitoring. Not described as a characteristic complication. Severity and organ effects are not quantified here. |
| Learning and developmental needs | Not a principal described complication. Delays and learning difficulties may require ongoing support. The range of additional health issues is not fully specified. |
Patient education highlights
- HighSpecialist follow-up
Both conditions need clinician-directed care; neither comparison replaces genetic or endocrine evaluation.
- HighTreatment approach
The enzyme disorder may require lifelong hormone replacement, while the microdeletion is managed supportively.
- MediumInheritance and testing
Family implications and confirmatory testing should be explained by a genetics professional.